U.S. Medical Equipment Stock News

The market reacted positively to DraftKings on the headline, with the stock jumping about 8% to roughly $24 after earnings, even though the quarter swung back to a loss. That move rests on one core idea: investors are treating adjusted EBITDA of $115 million and reaffirmed 2026 guidance of $700 million to $900 million as evidence that the profit story remains intact. Coming into the release, the stock had cooled over the past month and quarter. Today is a sentiment reset built around one key...

Evergy stock barely moved after earnings, ticking up about 0.4% to US$83.38, which suggests the market viewed the report as business as usual. The numbers, however, indicate a more detailed picture. Quarterly earnings per share were about US$0.93 and adjusted earnings per share for the quarter came in at US$0.88, with management reaffirming a US$4.24 full-year adjusted earnings midpoint. That calm price reaction sits alongside a broader consideration. Evergy is trading near 21x earnings while...

Lineage Cell Therapeutics slipped 2.7% to about US$1.10 after its second quarter report, a muted move for a stock that has already shed close to 20% over the past three months. The headline in this print is not the top line. It is the sharp squeeze between a tiny US$1.1 million in quarterly revenue and a much heavier cost base, even though this quarter showed a US$1.5 million net income on paper. That profit figure rests largely on noncash warrant revaluation. The key consideration for long...

Haemonetics stock came into this quarter on a tear, with shares up almost 60% over the past three months and another 3.3% added today. That kind of move sets a high bar. The headline from the print is straightforward: revenue reached US$339.4m and adjusted earnings per share landed at US$1.14, while management pushed full year revenue guidance higher. For a company long viewed as a steady blood and plasma technology compounder, the real story this quarter is not a growth scare. Instead, it is...

NexPoint Real Estate Finance stock added 3.3% today to close at US$18.17, capping a strong 30 day run. However, the real story sits in the cash engine behind that move. The headline from this mortgage REIT’s quarter is not basic earnings per share. It is that cash available for distribution covered the US$0.50 dividend at 1.16x, and the board still signed off on another US$0.50 for Q3. Short term traders are reacting to the bounce. Longer term investors are likely to focus on how this...

Tarsus Pharmaceuticals stock slipped 0.8% to US$64.79 after the Q2 print, a muted reaction for a company that just posted US$173.9m in quarterly net product sales from a single flagship drug. The market focused on another quarterly loss and the near term hit from heavier research and development spending. In the longer term, the story sits in a different place. Revenue over the past year has reached US$606.3m, management has raised 2026 sales guidance for XDEMVY, and the balance sheet held...

Amphastar Pharmaceuticals stock closed up 4.9% at US$20.78, yet the real story sits behind that modest relief rally. Q2 delivered a sharp earnings snapback, with basic earnings per share at US$0.70 on revenue of US$183.9m, and management leaning into share repurchases with about US$45m bought back in the quarter. The market is reacting to the quarter in front of it. The bigger question for you is how this drug maker’s margin pressure, earnings outlook and wide gap to the referenced fair value...

Palantir Technologies (PLTR) is back in focus after its second quarter 2026 earnings report, which showed revenue of US$1.94b and net income of US$1.06b, alongside a sharp stock move. See our latest analysis for Palantir Technologies. The second quarter results and raised 2026 guidance have come alongside a sharp shift in sentiment toward Palantir Technologies, with a 10.32% 1 day share price return and a 39.78% 7 day share price return, while the 1 year total shareholder return is down 8%...

OmniAb walked into this quarter with a reputation as a high multiple, high promise antibody discovery platform, and the stock has just been reminded of that. Shares jumped 37.5% to US$3.08 after the Q2 2026 release, a sharp move for a company that still reports losses but just posted US$13.4m in revenue and a much smaller net loss of US$5.9m. The real story for OmniAb this time is the earnings trend. Losses are shrinking while milestone revenue from partner drugs advancing in the clinic does...

MP Materials stock jumped 7.6% to US$51.11 after earnings, even though the company remained in the red this quarter. The market is reacting to a rare earths story that is now about scale, not quick profits. Revenue reached US$126.1m and adjusted profitability at the earnings before interest, tax, depreciation and amortisation level improved, yet basic earnings per share stayed negative. For short term traders, that mix can feel messy. For long term investors, the real headline is a rare...

Investors Title slipped about 2% today, even though the latest quarter delivered one of its punchiest earnings prints in recent memory. The stock had been grinding higher over the past three months, so this pullback may feel jarring if you came in expecting a clean victory lap. Q2 basic earnings per share of US$7.75 on revenue of US$86.5m reinforced that the title insurer can still generate solid profit in a choppy real estate market. The bigger question now is whether that margin strength...

The market barely shrugged at Realty Income’s earnings, with the stock edging up only 0.2% to about US$62.50, yet the headline from this quarter is quietly bigger. Adjusted funds from operations per share, the key cash flow gauge for a REIT, came in at US$1.09 and management lifted the full year outlook to about US$4.44 to US$4.45. For a stock that has drifted slightly lower over the past month and week, that kind of reaffirmed cash engine and higher guidance is the real story investors will...

Papa John’s International stock barely flinched after earnings, slipping only 0.7% to about US$24.50, even though the story was all about pressure and sacrifice. The headline this quarter is not the modest quarterly profit. It is the decision to suspend the rich 7.5% dividend in order to fund a multi year overhaul while global system sales declined and North America same store sales remained weak. The market reaction so far looks muted compared with that trade off. Investors now have to weigh...

Appian stock ripped higher today, jumping about 14% to US$34.64, as investors rushed to reprice a software platform that just reported another quarter of cloud growth and profit improvement. The headline is simple: cloud subscription revenue reached US$131.7m in Q2 and adjusted earnings before interest, tax, depreciation and amortisation came in at US$16.2m, strong enough for management to lift full year cloud and margin guidance. Short term traders reacted to the beat. Long term holders will...

Rigetti Computing just ripped 8.5% higher in a single session, yet the story behind that move is less euphoric. The headline this quarter is not revenue in isolation. It is the strain between quantum growth ambitions and an unprofitable earnings profile, with Q2 showing a net loss in the tens of millions of US dollars and basic earnings per share back in negative territory. Coming into the release, the stock had already swung sharply over the past three months and carried a rich price to book...

AerSale came into this print already under pressure, with the stock down roughly 10% over the past three months and now dropping another 6% to about US$5.90 after the release. The reaction reflects one thing above all else: profitability is moving the wrong way. Q2 revenue of US$70.9m sat well below the prior year level and the company posted a net loss of US$5.6m, extending the red ink seen earlier in 2026. For an aircraft leasing and maintenance specialist that many investors view as an...

Casella Waste Systems stock slipped about 1% to US$89.41 after its latest earnings, which looks like a mild shrug from the market compared with what the numbers actually say. You are looking at a solid waste operator that just produced US$543.7m in quarterly revenue and US$123.2m in adjusted earnings before interest, tax, depreciation and amortization, or adjusted EBITDA. Management also lifted full year revenue guidance while holding the EBITDA and free cash flow ranges steady. The real...

Airbnb stock just ripped 17% higher in a single session, and that is not the kind of move you usually see without a story to match. The story this time is simple. Revenue hit US$3.6b in the quarter and net income reached US$816m, both comfortably strong for a platform that lives and dies on travel demand and booking volume. The market is treating this as a sentiment reset on Airbnb. A rich P/E and questions about growth momentum were hanging over the stock coming into the print. This earnings...

Parker-Hannifin stock barely budged after earnings, inching up about 0.4% to roughly $1,074. On the screen it looked like just another quiet session. Under the surface the story is sharper. The company posted record full year revenue of about $21.5b and adjusted earnings per share above $30, while running an operating model that kept net profit margins near the mid teens. For a stock already trading on a rich P/E multiple, the real question for investors now is how long that earnings engine...

Inflation readings, central bank expectations and a fresh look at Berkshire Hathaway’s cash pile are giving investors new reasons to rethink where they want steady, large cap exposure. When price pressures and earnings updates hit in the same week, money often shifts quickly. This article walks through three large cap value stocks from our screener that appear closely tied to these stories and explains why their current setup might deserve your attention. The three stocks highlighted below...

Insmed stock slipped about 1% today, a muted reaction for a company that just reported a breakout biotech quarter. The market seems to be focusing on the recent run in the share price rather than the step change in the business. The headline is simple. BRINSUPRI delivered about US$309.2m in Q2 revenue and now carries full year guidance of US$1.25b to US$1.4b. Total quarterly revenue reached roughly US$425.5m. For a business that still reports a net loss, this kind of top line traction is what...

REGENXBIO dropped almost 5% to US$10.72 in the first trading session after its Q2 release, even though the headline numbers landed with real force. The company swung from heavy losses in recent quarters to basic earnings per share of about US$0.43 on revenue of roughly US$108 million. That surprise profit is only part of the story. What really matters for you now is how a newly extended cash runway, backed by recent AbbVie funding and an equity raise, may reshape the multi year risk and...

Somnigroup International stock barely moved on the print, edging up about 0.6% to US$65.25, even though earnings landed as one of the cleaner positives in a tough bedding market. The short term story is simple. Adjusted earnings per share in Q2 came in at US$0.58 with adjusted EBITDA of US$297m, both pointing to solid execution rather than a surprise swing. The longer term story is where things get interesting. Trailing 12 month earnings per share of US$2.54 now sit against a P/E of 25.7x,...

Tractor Supply stock inched up about 1.4% to US$34.56 after the Q2 release, a calm move for a retailer that just told investors its profit engine is under more pressure. The headline is a modest sales lift to US$4.5b paired with earnings that fell short of expectations and a lower comparable sales outlook. That is a mix that often stirs more anxiety in specialty retail than a 1 day gain suggests. The real story is the margin squeeze behind those numbers. Traders appear to be pricing in a...